are specific subgroups of patients characterized by biomarkers that may have important therapeutic responses. Without collecting DNA and biomarkers carefully in all clinical trials of therapeutic interventions, we may be discarding valuable information about therapies in targeted populations. Our oncology colleagues have advanced this strategy of a more personalized approach based on biomarkers and DNA profile for chemotherapeutic interventions to a much greater extent than we have in cardiology.
At JACC: Heart Failure, we are committed to publishing important investigations around biomarker development; whether to improve diagnosis, prognosis, or more importantly, determining subgroups of patients who may respond more favorably to certain therapies. We are committed to advancing this field of knowledge, so it will be easier to balance a benefit/risk ratio into the clinical setting to help improve quality and duration of life for our much needed heart failure patients.
